SureTrader
Interactive Brokers Advertisement
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board: 
Last Post: 12/10/2017 9:57:00 PM - Followers: 1369 - Board type: Free - Posts Today: 0

Biotech Values is a forum for discussing 
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Calendars and Compilations
Webcasts
FDA Calendar
Recent Biotech Buyouts

Buyouts of Biotech Partners
Common Biotech-Newbie Mistakes
Biotech Holdings of Selected Institutional Investors
US Patent Expirations for Big-Selling Biologics
Biotech and Miscellaneous Acronyms

Top Twitter Feeds for Biotech Info
iHub's Greatest Hits (thru 5/09)

SureTrader
Interactive Brokers Advertisement
PostSubject
#215887  Sticky Note SYRS—…this drug [SY-1425] is a complete dud. DewDiligence 12/10/17 04:20:34 PM
#215885  Sticky Note (GILD/NVS/etc)—NEJM editorial on the state of CAR-T: DewDiligence 12/10/17 04:01:13 PM
#215871  Sticky Note SRPT iwfal 12/09/17 02:33:37 PM
#215861  Sticky Note ONCE > A Cure for Hemophilia within Reach biocqr 12/09/17 10:41:07 AM
#215815  Sticky Note Re: RVNC valuation …do you still DewDiligence 12/07/17 06:48:01 PM
#215793  Sticky Note ASH Analyst/Investor Events (updated) ghmm 12/07/17 11:26:14 AM
#215891   One day I'm going to figure out how mcbio 12/10/17 09:57:00 PM
#215890   Poorgrad....re your statement Whalatane 12/10/17 07:35:36 PM
#215889   SYRS: One day I'm going to figure out how poorgradstudent 12/10/17 06:17:39 PM
#215888   >>They have some convertible preferred stock that's excluded biomaven0 12/10/17 05:48:13 PM
#215887   SYRS—…this drug [SY-1425] is a complete dud. DewDiligence 12/10/17 04:20:34 PM
#215886   ASH’s own PR summarizing CAR-T presentations at the conference: DewDiligence 12/10/17 04:05:43 PM
#215885   (GILD/NVS/etc)—NEJM editorial on the state of CAR-T: DewDiligence 12/10/17 04:01:13 PM
#215884   It's not my number, it's TRIL's number. You rkrw 12/09/17 08:34:44 PM
#215883   He conveniently omits real facts like Sarepta's "plunge" iwfal 12/09/17 07:26:32 PM
#215882   Updates to Nasdaq Biotech Index—effective 12/18/17: DewDiligence 12/09/17 05:59:29 PM
#215881   Charles Seife / SRPT: ghmm 12/09/17 05:52:33 PM
#215880   Still assuming the biggest thing for SRPT is iwfal 12/09/17 05:21:36 PM
#215879   SRPT iwfal 12/09/17 05:17:32 PM
#215878   AMGN ASH CC slides: DewDiligence 12/09/17 04:13:54 PM
#215877   We don't. However, one of the slides with mcbio 12/09/17 04:10:56 PM
#215876   We don't. However, one of the slides with DewDiligence 12/09/17 04:05:30 PM
#215875   (INCY)—IMV.TO +36% last week on these dataI saw mcbio 12/09/17 04:02:44 PM
#215874   (INCY)—IMV.TO +36% last week on these data: DewDiligence 12/09/17 03:59:15 PM
#215873   SRPT - And I would suggest the most mcbio 12/09/17 03:39:21 PM
#215872   Clark, Under what statutory authority does the FDA have bladerunner1717 12/09/17 02:43:19 PM
#215871   SRPT iwfal 12/09/17 02:33:37 PM
#215870   BMRN - Hemophilia A ghmm 12/09/17 02:05:51 PM
#215869   Edit - I quoted/highlighted the BMRN data..not ONCE. biocqr 12/09/17 01:40:02 PM
#215868   biocqr, I'm a little confused (not unusual). Is this jbog 12/09/17 01:12:35 PM
#215867   Comprehensive analysis of the clinical immuno-oncology landscape Titan V 12/09/17 01:11:17 PM
#215866   mcbio. re " why is it that Whalatane 12/09/17 01:06:05 PM
#215865   Of course. Makes perfect sense. marthambles 12/09/17 12:55:43 PM
#215864   Re: Re: RVNC trial in plantar fasciitis DewDiligence 12/09/17 12:41:09 PM
#215863   VTVT > Dew, Peter and the board in biocqr 12/09/17 12:37:54 PM
#215862   RE cancer drug price competition. Implications for nowlurking 12/09/17 10:59:26 AM
#215861   ONCE > A Cure for Hemophilia within Reach biocqr 12/09/17 10:41:07 AM
#215860   BioMarin Provides 1.5 years of Clinical Data for jbog 12/09/17 07:55:39 AM
#215859   VKTX/MDGL - Titan. I read a P1 trial mcbio 12/08/17 11:35:40 PM
#215858   I don't know how outstanding shares are counted xavierprivas 12/08/17 10:55:09 PM
#215857   I understand there is no comparator botox arm. marthambles 12/08/17 10:10:01 PM
#215856   For SEC reporting purposes, only basic shares and bladerunner1717 12/08/17 08:35:28 PM
#215855   For SEC reporting purposes, only basic shares and DewDiligence 12/08/17 08:25:56 PM
#215854   TRIL. I was told 16.9 common+preferred, plus 2.315m bladerunner1717 12/08/17 08:20:48 PM
#215853   Re: RVNC trial in plantar fasciitis DewDiligence 12/08/17 07:53:47 PM
#215852   TRIL. I was told 16.9 common+preferred, plus 2.315m rkrw 12/08/17 05:52:21 PM
#215851   re: TRIL bladerunner1717 12/08/17 05:23:18 PM
#215850   LLY—Cyramza in first-line gastric cancer hits PFS (primary) DewDiligence 12/08/17 05:19:48 PM
#215849   TRIL real float must be small.Nasdaq site says linhdtu 12/08/17 03:39:17 PM
#215848   DNLI - sounds like a big gamble at mcbio 12/08/17 03:13:57 PM
#215847   RVNC - regarding the PF trial, botox is marthambles 12/08/17 03:06:41 PM
#215846   Liver Drug Hype and Pain Unlikely to End jbog 12/08/17 02:50:37 PM
#215845   TRIL > Matrix Capital reports 16.5% ownership. biocqr 12/08/17 02:48:02 PM
#215844   Sam Isaly steps down from hedge fund giant biotech_researcher 12/08/17 01:05:50 PM
#215843   These are important considerations Whalatane. Thank you for Titan V 12/08/17 01:03:17 PM
#215842   SCMP Exploring Sale on Rumored Takeover Interest https://www.biospace.com/articl Titan V 12/08/17 01:00:35 PM
PostSubject